Inhibitor Therapeutics Stock Market Value
| INTI Stock | USD 0.04 0.00 0.00% |
| Symbol | Inhibitor |
Inhibitor Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Inhibitor Therapeutics' otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Inhibitor Therapeutics.
| 09/30/2025 |
| 12/29/2025 |
If you would invest 0.00 in Inhibitor Therapeutics on September 30, 2025 and sell it all today you would earn a total of 0.00 from holding Inhibitor Therapeutics or generate 0.0% return on investment in Inhibitor Therapeutics over 90 days. Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patient... More
Inhibitor Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Inhibitor Therapeutics' otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Inhibitor Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 11.88 | |||
| Information Ratio | 0.0172 | |||
| Maximum Drawdown | 68.18 | |||
| Value At Risk | (15.79) | |||
| Potential Upside | 14.0 |
Inhibitor Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Inhibitor Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Inhibitor Therapeutics' standard deviation. In reality, there are many statistical measures that can use Inhibitor Therapeutics historical prices to predict the future Inhibitor Therapeutics' volatility.| Risk Adjusted Performance | 0.0276 | |||
| Jensen Alpha | 0.3157 | |||
| Total Risk Alpha | (0.78) | |||
| Sortino Ratio | 0.0138 | |||
| Treynor Ratio | (0.23) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Inhibitor Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Inhibitor Therapeutics Backtested Returns
Inhibitor Therapeutics appears to be out of control, given 3 months investment horizon. Inhibitor Therapeutics holds Efficiency (Sharpe) Ratio of 0.0243, which attests that the entity had a 0.0243 % return per unit of risk over the last 3 months. We have found twenty-five technical indicators for Inhibitor Therapeutics, which you can use to evaluate the volatility of the firm. Please utilize Inhibitor Therapeutics' Risk Adjusted Performance of 0.0276, market risk adjusted performance of (0.22), and Downside Deviation of 11.88 to validate if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Inhibitor Therapeutics holds a performance score of 1. The company retains a Market Volatility (i.e., Beta) of -1.02, which attests to a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Inhibitor Therapeutics are expected to decrease slowly. On the other hand, during market turmoil, Inhibitor Therapeutics is expected to outperform it slightly. Please check Inhibitor Therapeutics' total risk alpha, as well as the relationship between the potential upside and kurtosis , to make a quick decision on whether Inhibitor Therapeutics' current trending patterns will revert.
Auto-correlation | -0.03 |
Very weak reverse predictability
Inhibitor Therapeutics has very weak reverse predictability. Overlapping area represents the amount of predictability between Inhibitor Therapeutics time series from 30th of September 2025 to 14th of November 2025 and 14th of November 2025 to 29th of December 2025. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Inhibitor Therapeutics price movement. The serial correlation of -0.03 indicates that only 3.0% of current Inhibitor Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.03 | |
| Spearman Rank Test | -0.51 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Inhibitor Therapeutics lagged returns against current returns
Autocorrelation, which is Inhibitor Therapeutics otc stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Inhibitor Therapeutics' otc stock expected returns. We can calculate the autocorrelation of Inhibitor Therapeutics returns to help us make a trade decision. For example, suppose you find that Inhibitor Therapeutics has exhibited high autocorrelation historically, and you observe that the otc stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Inhibitor Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Inhibitor Therapeutics otc stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Inhibitor Therapeutics otc stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Inhibitor Therapeutics otc stock over time.
Current vs Lagged Prices |
| Timeline |
Inhibitor Therapeutics Lagged Returns
When evaluating Inhibitor Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Inhibitor Therapeutics otc stock have on its future price. Inhibitor Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Inhibitor Therapeutics autocorrelation shows the relationship between Inhibitor Therapeutics otc stock current value and its past values and can show if there is a momentum factor associated with investing in Inhibitor Therapeutics.
Regressed Prices |
| Timeline |
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Inhibitor OTC Stock
Inhibitor Therapeutics financial ratios help investors to determine whether Inhibitor OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Inhibitor with respect to the benefits of owning Inhibitor Therapeutics security.